Press Releases for ALNY

Press Releases
Cubist Pharmaceuticals 3rd Quarter Total Net Revenues Up 28%
Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics in Oncology
Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics
Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results
Alnylam and Tekmira Participate in New Research Collaboration
Alnylam to Webcast Conference Call Discussing Second Quarter 2009 Financial Results
INSERTING and REPLACING Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis
Alnylam's Kreutzer-Limmer II Patent Upheld in European Opposition Proceedings
Alnylam’s Kreutzer-Limmer II Patent Upheld in European Opposition Proceedings
Alnylam Joins GSK in Donating Intellectual Property to Patent Pool for Neglected Tropical Diseases
Alnylam Joins Max Planck in Legal Action toward Whitehead Institute
Alnylam and Collaborators Present New Pre-Clinical Research Findings on RNAi Therapeutics Targeting PCSK9, a Genetically Validated Regulator of LDL Metabolism
Alnylam to Webcast Presentation at Jefferies 3rd Annual Healthcare Conference
Alnylam to Webcast Conference Call to Discuss Preliminary Data from Phase II Study of ALN-RSV01
Alnylam and Cubist Report Preliminary Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
Alnylam to Webcast Presentation at the 8th Annual Needham Life Sciences Conference
Alnylam Named to The Scientist Magazine’s 2009 Best Places to Work in Industry
Regulus Therapeutics Achieves Initial Milestone in its Inflammatory Diseases Collaboration with GlaxoSmithKline
Alnylam Pharmaceuticals Reports First Quarter 2009 Financial Results
Novartis Exercises its Right to Purchase Additional Shares of Alnylam Common Stock
Alnylam to Webcast Conference Call Discussing First Quarter 2009 Financial Results
Isis and Alnylam Form New Collaboration to Develop Single-Stranded RNAi Technology
Alnylam Granted New Fundamental Patent in China Broadly Covering RNAi Therapeutics
Cubist Pharmaceuticals 1Q09 Total Net Revenues Up 37%; Total Net Revenues $121.1 Million; Net Product Revenues $114.6 Million
Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics
Alnylam Initiates Phase I Clinical Study of ALN-VSP in Patients with Liver Cancer
Alnylam to Webcast Presentation at the Cowen and Company 29th Annual Health Care Conference
Alnylam and Collaborators at MIT Publish New In Vivo Research on Systemic Delivery of RNAi Therapeutics
Alnylam to Webcast Presentation at the Barclays Capital Global Healthcare Conference
Alnylam Pharmaceuticals Reports Fourth Quarter and 2008 Financial Results
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2008 Financial Results
Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium
Alnylam and Collaborators Publish New Pre-Clinical Research Demonstrating In Vivo Efficacy of Systemically Delivered RNAi Therapeutics in Ovarian Cancer
Alnylam Receives Grant of New Patent Broadly Covering RNAi Therapeutics
Alnylam to Webcast Presentation at the 11th Annual BIO CEO & Investor Conference
Alnylam Promotes Akshay Vaishnaw to Senior Vice President, Clinical Research
Alnylam Receives Clearance from FDA to Initiate Phase I Study with ALN-VSP for the Treatment of Liver Cancers
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)
Alnylam Provides Key Goals and Guidance for 2009
Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection
Alnylam to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
Alnylam Advances RNAi Therapeutics Pipeline and Files Company’s First Systemic Delivery IND
Alnylam Publishes Pre-Clinical Research on Direct CNS Delivery of RNAi Therapeutics
Alnylam Pharmaceuticals and Roche Collaboration Selected as Best Partnership Alliance by Scrip
Alnylam Forms Collaboration with University of California, San Francisco (UCSF) to Investigate Therapeutic Silencing of Key Gene Implicated in Uveal Melanoma
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Alnylam Strengthens Intellectual Property Estate through Acquisition of Nucleonics Patent Assets
Alnylam Selected as 2009 Technology Pioneer by the World Economic Forum
Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
Alnylam to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
Alnylam Presents Pre-clinical Data from TTR Amyloidosis Development Program
IMM, Cenix, and Alnylam Discover New Targets in Malaria Infection with RNAi Technology
Alnylam to Webcast Presentation at the Rodman & Renshaw 10th Annual Healthcare Conference
Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis
Alnylam Pharmaceuticals Reports Third Quarter 2008 Financial Results
Alnylam and Collaborators Publish New Pre-clinical Research on Therapeutic Silencing of Key Gene Implicated in Parkinson's Disease
Alnylam and Collaborators Publish Research on a New Class of Chemically Modified RNAi Therapeutics that Target Two Distinct Cellular Mechanisms
Alnylam to Webcast Conference Call Discussing Third Quarter 2008 Financial Results
Alnylam to Webcast Presentation at the Seventh Annual BIO Investor Forum
Alnylam Scientists Present Data from Multiple Programs at the 4th Annual Meeting of the Oligonucleotide Therapeutics Society
Alnylam Earns $20 Million Payment from Takeda
Alnylam to Webcast Presentation at The Third Annual JMP Securities Healthcare Focus Conference
Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer
Alnylam to Webcast Presentation at UBS 2008 Global Life Sciences Conference
Instituto de Medicina Molecular, Cenix BioScience, and Alnylam Pharmaceuticals Discover New Pathway for Malaria Infection
Alnylam to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Alnylam to Webcast Presentation at NewsMakers in the Biotech Industry Conference
Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors
Zacks Analyst Blog Highlights: HCP, Inc., The Ryland Group, Inc., Alnylam Pharmaceuticals, Inc., Novartis AG and Corrections Corp. Of America
Alnylam and Collaborators Publish New Pre-Clinical Research on RNAi-Mediated Silencing of PCSK9, a Genetically Validated Regulator of LDL Metabolism
Alnylam Forms Collaboration with Max Planck Institute to Investigate Biological Mechanisms for Cellular Uptake of RNAi Therapeutics
Alnylam Pharmaceuticals Reports Second Quarter 2008 Financial Results
Alnylam Awarded Continued Funding Under U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats
Alnylam Withdraws from Bank of America 2008 Specialty Pharmaceuticals Conference
Alnylam Consolidates Intellectual Property for RNA Activation (RNAa), a New Biological Discovery for Activation of Gene Expression
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
Alnylam to Webcast Presentation at the Bank of America 2008 Specialty Pharmaceuticals Conference
Alnylam to Webcast Conference Call Discussing Second Quarter 2008 Financial Results
Alnylam Grants New InterfeRx(TM) Intellectual Property License to Calando for Development and Commercialization of RNAi Therapeutics
Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis
Alnylam Provides Update on "Glover" Patent
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
Alnylam and Kyowa Hakko Form Alliance for the Development and Commercialization of ALN-RSV01 in Asia
Alnylam to Webcast Presentation at the 2008 Piper Jaffray Europe Conference
Alnylam Announces Close of Investment and Expanded Agreement Related to the Tekmira-Protiva Business Combination
Isis to Receive $4.6 Million From Alnylam
Alnylam to Webcast Conference Call to Discuss Takeda Alliance
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
Alnylam and Collaborators Publish In Vivo Research on Validation of a Mammalian Host Gene Involved in Malaria Infection and on the Anti-Parasitic Efficacy of RNAi Therapeutics - May 27 2008 1:00AM
Alnylam to Webcast Presentation at the Bank of America 2008 Health Care Conference - Jun 1 2008 7:07AM
Alnylam to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference - Jun 1 2008 7:07AM
Alnylam Pharmaceuticals Reports First Quarter 2008 Financial Results - Jun 1 2008 7:07AM
Novartis Exercises Rights to Purchase Additional Shares of Alnylam's Common Stock in Accordance with Terms of Existing Investor Rights Agreement - Jun 1 2008 7:07AM
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases - Jun 1 2008 7:06AM
Alnylam to Webcast Conference Call Discussing First Quarter 2008 Financial Results - Jun 1 2008 7:06AM
Alnylam to Webcast Presentation at the Deutsche Bank 33rd Annual Health Care Conference